Sonja Zweegman
Vrije Universiteit Medical Center (VUMC) · Amsterdam UMC · Amsterdam UMC, location VUmc
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sonja Zweegman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:03 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07107529 · Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.European Myeloma Network B.V. · recruiting · Multiple Myeloma (MM) · principal investigator
- Ph3NCT06187441 · FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)Stichting Hemato-Oncologie voor Volwassenen Nederland · recruiting · Multiple Myeloma · principal investigator
- Ph4NCT05555329 · Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative StudyAmsterdam UMC, location VUmc · completed · Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory · principal investigator
- Ph4NCT02149329 · Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUOAmsterdam UMC, location VUmc · completed · Febrile Neutropenia, Hematological Malignancy · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:03 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 13:03 UTC. The ranking covers the 200 most relevant of 50 PubMed records, and a shared surname and initials can bring in a namesake. All 50 on PubMed
- 854 citationsRCR 35.4
- Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.J Clin Oncol · 2012664 citationsRCR 18.1
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.Blood · 2016350 citationsRCR 10.9
- 328 citationsRCR 15.2
- 225 citationsRCR 5.8
- Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.J Clin Oncol · 2010223 citationsRCR 5.8
- 208 citationsRCR 7.8
- 171 citationsRCR 4.1
- Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.Leukemia · 2018167 citationsRCR 5.9
- 164 citationsRCR 9.3